Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $14.48, but opened at $13.19. Entrada Therapeutics shares last traded at $15.08, with a volume of 44,361 shares traded. Analysts Set New Price Targets Several brokerages recently issued reports on TRDA. […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) – Stock analysts at HC Wainwright raised their Q2 2023 earnings per share (EPS) estimates for Entrada Therapeutics in a report released on Wednesday, May 24th. HC Wainwright analyst B. Pachaiyappan now expects that the company will earn ($0.23) per share for the quarter, up from their previous […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) – Investment analysts at William Blair upped their Q2 2023 EPS estimates for Entrada Therapeutics in a research report issued on Wednesday, May 10th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.62) per share for the quarter, up from their prior […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) – William Blair raised their Q2 2023 EPS estimates for Entrada Therapeutics in a report issued on Wednesday, May 10th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.62) for the quarter, up from their prior estimate of ($0.74). William […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 2,000 shares of the business’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $13.71, for a total transaction of $27,420.00. Following the sale, the chief executive officer now owns 202,069 shares in the company, valued […]